Effect of XELIRINOX in the treatment of gastric cancer
Phase 3
- Conditions
- Malignant neoplasm of stomach.Malignant neoplasm of stomach
- Registration Number
- IRCT2014112618842N4
- Lead Sponsor
- Hematology-Oncology & Stem Cell Research Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 43
Inclusion Criteria
All patients with metastatic gastric cancer who have not previously received any chemotherapy; All patients with metastatic gastric cancer without an appropriate response to previous treatments; signing informed consent form; have a life expectancy of at least 12 weeks; Patients who can be followed up. Exclusion criteria:Patients who have non metastatic gastric cancer; Patients who have a debilitating underlying disease; Patients who develop complications during treatment due to chemotherapy or gastric cancer.
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Response to Treatment. Timepoint: 3 and 6 weeks after stat treatment. Method of measurement: using Response Evaluation Criteria in Solid Tumors (RECIST).
- Secondary Outcome Measures
Name Time Method Overall Survival. Timepoint: One year after start treatment. Method of measurement: Follow-up Patient.;Progression-free Survival. Timepoint: 12 months after start treatment. Method of measurement: Patient Follow-up Visit to Assess the Progress of the Disease by CT Scan.